We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00184899
First Posted: September 16, 2005
Last Update Posted: March 1, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Radboud University
  Purpose

The metabolic syndrome is associated with hyperdynamic circulation and sympathetic activation. Recently, Bakker et al. (Atherosclerosis 2002) described the hypothesis that free fatty acids are responsible for this association. The investigators hypothesize that in patients with obesity and the metabolic syndrome, an increased intracellular concentration of long-chain fatty acyl (LCFA)-CoA (the intracellular equivalent of free fatty acids) induces an increase in adenosine. Adenosine receptor stimulation, in turn, induces vasodilation and sympathetic activation.

The investigators aimed to assess this effect of free fatty acids on the adenosine system in healthy volunteers.


Condition Intervention
Obesity Metabolic Syndrome X Drug: Intravenous infusion of Intralipid/heparin Drug: Intravenous infusion of Glycerol/heparin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Educational/Counseling/Training
Official Title: The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids

Resource links provided by NLM:


Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Forearm blood flow
  • Vasoactive effect of caffeine
  • Sympathetic activity (noradrenaline spillover, spectral analysis)

Estimated Enrollment: 20
Study Start Date: August 2005
Estimated Study Completion Date: August 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers

Exclusion Criteria:

  • Pregnancy
  • Asthma
  • Use of medication
  • Cardiovascular/pulmonary disease and diabetes
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184899


Locations
Netherlands
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500HB
Sponsors and Collaborators
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Principal Investigator: Paul Smits, MD, PhD Radboud University
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00184899     History of Changes
Other Study ID Numbers: Intralipid-Ado
ZonMw Nr. 920-03-249
First Submitted: September 12, 2005
First Posted: September 16, 2005
Last Update Posted: March 1, 2007
Last Verified: February 2007

Keywords provided by Radboud University:
free fatty acids
vasodilation
sympathetic activity

Additional relevant MeSH terms:
Metabolic Syndrome X
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Calcium heparin
Heparin
Adenosine
Soybean oil, phospholipid emulsion
Glycerol
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Fat Emulsions, Intravenous
Parenteral Nutrition Solutions
Pharmaceutical Solutions
Cryoprotective Agents
Protective Agents